Search Results - "Oyama, M.A."

Differentiation of Cardiac from Noncardiac Pleural Effusions in Cats using Second‐Generation Quantitative and Point‐of‐Care NT‐proBNP Measurements by Hezzell, M.J., Rush, J.E., Humm, K., Rozanski, E.A., Sargent, J., Connolly, D.J., Boswood, A., Oyama, M.A.

“…BACKGROUND: Pleural effusion is a common cause of dyspnea in cats. N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) measurement, using a first‐generation…”
Get full text

Multicenter Evaluation of Plasma N-Terminal Probrain Natriuretic Peptide (NT-pro BNP) as a Biochemical Screening Test for Asymptomatic (occult) Cardiomyopathy in Cats by Fox, P.R., Rush, J.E., Reynolds, C.A., DeFrancesco, T.C., Keene, B.W., Atkins, C.E., Gordon, S.G., Schober, K.E., Bonagura, J.D., Stepien, R.L., Kellihan, H.B., MacDonald, K.A., Lehmkuhl, L.B., Nguyenba, T.P., Sydney Moise, N., Lefbom, B.K., Hogan, D.F., Oyama, M.A.

“…Background: B‐type natriuretic peptide concentrations reliably distinguish between cardiac and respiratory causes of dyspnea, but its utility to detect…”
Get full text

Serotonin Concentrations in Platelets, Plasma, Mitral Valve Leaflet, and Left Ventricular Myocardial Tissue in Dogs with Myxomatous Mitral Valve Disease by Cremer, S.E, Singletary, G.E, Olsen, L.H, Wallace, K, Häggström, J, Ljungvall, I, Höglund, K, Reynolds, C.A, Pizzinat, N, Oyama, M.A

“…HYPOTHESIS/OBJECTIVES: Altered serotonin (5‐hydroxytryptamine, 5HT) signaling is postulated in development and progression of canine myxomatous mitral valve…”
Get full text

Perceptions of Quality of Life and Priorities of Owners of Cats with Heart Disease by Reynolds, C.A, Oyama, M.A, Rush, J.E, Rozanski, E.A, Singletary, G.E, Brown, D.C, Cunningham, S.M, Fox, P.R, Bond, B, Adin, D.B, Williams, R.M, MacDonald, K.A, Malakoff, R, Sleeper, M.M, Schober, K.E, Petrie, J.P

“…Background: Owners' perceptions and priorities regarding quality of life (QoL) are important considerations given the unknown efficacy of many commonly…”
Get full text

Strong association between activated valvular interstitial cells and histopathological lesions in porcine model of induced mitral regurgitation by Cremer, S.E, Zois, N.E, Moesgaard, S.G, Ravn, N, Cirera, S, Honge, J.L, Smerup, M.H, Hasenkam, J.M, Sloth, E, Leifsson, P.S, Falk, T, Oyama, M.A, Orton, C, Martinussen, T, Olsen, L.H

Get full text

Decreased Triadin and Increased Calstabin2 Expression in Great Danes with Dilated Cardiomyopathy by Oyama, M.A, Chittur, S.V, Reynolds, C.A

“…Background: Dilated cardiomyopathy (DCM) is a common cardiac disease of Great Dane dogs, yet very little is known about the underlying molecular abnormalities…”
Get full text

Letter to the Editor by Oyama, M.A.

Get full text

Letter to the Editor by Oyama, M.A.

Get full text

Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study—A Randomized Clinical Trial by Boswood, A., Häggström, J., Gordon, S.G., Wess, G., Stepien, R.L., Oyama, M.A., Keene, B.W., Bonagura, J., MacDonald, K.A., Patteson, M., Smith, S., Fox, P.R., Sanderson, K., Woolley, R., Szatmári, V., Menaut, P., Church, W.M., O'Sullivan, M. L., Jaudon, J.‐P., Kresken, J.‐G., Rush, J., Barrett, K.A., Rosenthal, S.L., Saunders, A.B., Ljungvall, I., Deinert, M., Bomassi, E., Estrada, A.H., Fernandez Del Palacio, M.J., Moise, N.S., Abbott, J.A., Fujii, Y., Spier, A., Luethy, M.W., Santilli, R.A., Uechi, M., Tidholm, A., Watson, P.

“…Background Pimobendan is effective in treatment of dogs with congestive heart failure (CHF) secondary to myxomatous mitral valve disease (MMVD). Its effect on…”
Get full text

Retrospective Evaluation of the Effect of Heart Rate on Survival in Dogs with Atrial Fibrillation by Pedro, B., Dukes‐McEwan, J., Oyama, M.A., Kraus, M.S., Gelzer, A.R.

“…Background Atrial fibrillation (AF) usually is associated with a rapid ventricular rate. The optimal heart rate (HR) during AF is unknown…”
Get full text

Clinical Trials in Veterinary Medicine: A New Era Brings New Challenges by Oyama, M.A., Ellenberg, S.S., Shaw, P.A.

“…Randomized clinical trials (RCTs) are among the most rigorous ways to determine the causal relationship between an intervention and important clinical outcome…”
Get full text

Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Study by Boswood, A., Gordon, S.G., Häggström, J., Wess, G., Stepien, R.L., Oyama, M.A., Keene, B.W., Bonagura, J., MacDonald, K.A., Patteson, M., Smith, S., Fox, P.R., Sanderson, K., Woolley, R., Szatmári, V., Menaut, P., Church, W.M., O'Sullivan, M.L., Jaudon, J.‐P., Kresken, J.‐G., Rush, J., Barrett, K.A., Rosenthal, S.L., Saunders, A.B., Ljungvall, I., Deinert, M., Bomassi, E., Estrada, A.H., Fernandez Del Palacio, M.J., Moise, N.S., Abbott, J.A., Fujii, Y., Spier, A., Luethy, M.W., Santilli, R.A., Uechi, M., Tidholm, A., Schummer, C., Watson, P.

“…Background Changes in clinical variables associated with the administration of pimobendan to dogs with preclinical myxomatous mitral valve disease (MMVD) and…”
Get full text

Efficacy of Pimobendan in the Prevention of Congestive Heart Failure or Sudden Death in Doberman Pinschers with Preclinical Dilated Cardiomyopathy (The PROTECT Study) by Summerfield, N.J., Boswood, A., O'Grady, M.R., Gordon, S.G., Dukes‐McEwan, J., Oyama, M.A., Smith, S., Patteson, M., French, A.T., Culshaw, G.J., Braz‐Ruivo, L., Estrada, A., O'Sullivan, M.L., Loureiro, J., Willis, R., Watson, P.

“…Background The benefit of pimobendan in delaying the progression of preclinical dilated cardiomyopathy (DCM) in Dobermans is not reported. Hypothesis That…”
Get full text

P2311A novel HFpEF model has cardiac and pulmonary impairments similar to those in human HFpEF patients by Wallner, M., Berretta, R.M., Eaton, D.M., Borghetti, G., Wu, J., Baker, S.T., Troupes, C.D., Sharp, T.E., Feldsott, E.A., Oyama, M.A., Fox, P.R., Wolfson, M.R., Houser, S.R.

Get full text

Measurements of echocardiographic indices and biomarkers of kidney injury in dogs with chronic kidney disease by Hezzell, M.J., Foster, J.D., Oyama, M.A., Buch, J., Farace, G., Quinn, J.J., Yerramilli, M.

“…•Cardiovascular dysfunction secondary to chronic kidney disease (CKD) is a leading cause of death in human CKD patients.•CKD is common in veterinary patients,…”
Get full text

Differentiation of Cardiac from Noncardiac Pleural Effusions in Cats using Second‐Generation Quantitative and Point‐of‐Care NT ‐pro BNP Measurements by Hezzell, M.J., Rush, J.E., Humm, K., Rozanski, E.A., Sargent, J., Connolly, D.J., Boswood, A., Oyama, M.A.

“…Background Pleural effusion is a common cause of dyspnea in cats. N‐terminal pro‐B‐type natriuretic peptide ( NT ‐pro BNP ) measurement, using a…”
Get full text

Quiet timer blanking in a dog with sick sinus syndrome and a permanent transvenous pacemaker by Crooks, A.V., Gelzer, A.R., Oyama, M.A., Kraus, M.S.

“…A 14-year-old, 5.8 kg (12.7 lb) male castrated Jack Russell Terrier was referred for investigation of syncope and an arrhythmia. Electrocardiogram showed…”
Get full text

Insights into Serotonin Signaling Mechanisms Associated with Canine Degenerative Mitral Valve Disease by Oyama, M.A., Levy, R.J.

“…Little is known about the molecular abnormalities associated with canine degenerative mitral valve disease (DMVD). The pathology of DMVD involves the…”
Get full text

Clinical utility of serum N-terminal pro-B-type natriuretic peptide concentration for identifying cardiac disease in dogs and assessing disease severity by Oyama, M.A, Fox, P.R, Rush, J.E, Rozanski, E.A, Lesser, M

“…To determine whether serum N-terminal pro-B-type natriuretic (NT-proBNP) concentration could be used to identify cardiac disease in dogs and to assess disease…”
Get full text

Prognostic Importance of Myocardial Injury in Critically Ill Dogs with Systemic Inflammation by Langhorn, R., Oyama, M.A., King, L.G., Machen, M.C., Trafny, D.J., Thawley, V., Willesen, J.L., Tarnow, I., Kjelgaard-Hansen, M.

“…Background In noncardiac critical disease in humans, myocardial injury as detected by cardiac troponin I and T (cTnI and cTnT) has been linked to high…”
Get full text